Turn down the volume on desire itself, without silencing normal motivation
For decades, addiction has resisted medicine's best efforts, leaving millions caught in cycles of relapse with few effective tools. Now, a class of drugs already trusted for diabetes and obesity — GLP-1 receptor agonists like semaglutide and liraglutide — is drawing serious scientific attention for its ability to quiet the brain's reward circuitry and reduce the pull of alcohol, cocaine, nicotine, and opioids. The evidence, gathered largely from animal studies and reviewed in the British Journal of Pharmacology, is promising enough to warrant cautious hope, though the distance between a rat study and a human prescription remains one of medicine's most humbling stretches.
- Addiction treatment has long been underpowered — relapse rates remain stubbornly high and approved medications cover only a fraction of substance use disorders.
- GLP-1 drugs appear to blunt dopamine surges in the brain's reward pathway, reducing drug- and alcohol-seeking behavior across multiple species and substances in preclinical studies.
- Because these medications already carry established safety profiles from diabetes and obesity treatment, they could reach addiction clinics faster than entirely new compounds — if clinical trials confirm they work in humans.
- Early human signals are emerging: a pilot trial found exenatide improved smoking abstinence, and two clinical trials are now testing weekly exenatide injections in patients with alcohol use disorder.
- Critical unknowns remain — how the drugs perform in severe dependence, whether effects differ by sex, and what long-term use looks like — keeping clinical recommendation firmly in the future.
Millions of people struggle each year with addiction to alcohol, opioids, cocaine, and nicotine, yet available treatments remain limited and relapse rates stay stubbornly high. A recent review in the British Journal of Pharmacology asks whether drugs already prescribed for diabetes and obesity — GLP-1 receptor agonists including semaglutide, liraglutide, and exenatide — might offer a new path by dampening the brain's reward signals.
The mechanism centers on dopamine. When someone uses alcohol or cocaine, dopamine floods the brain's mesolimbic reward pathway, reinforcing the behavior. GLP-1 drugs appear to blunt that surge without shutting down the reward system entirely. In animal studies, liraglutide, exenatide, and dulaglutide all reduced alcohol consumption; in alcohol-prone African vervet monkeys, two of these drugs decreased drinking without causing nausea. Dulaglutide was notably consistent, lowering drinking in both male and female rats without tolerance developing over time.
The promise extends to other substances. Preclinical studies show GLP-1 agonists can reduce cocaine self-administration and relapse-like behavior, while nicotine research has produced an early human signal: a pilot trial found exenatide combined with nicotine replacement therapy improved abstinence and reduced cravings. Evidence for opioid dependence is more mixed, though human trials testing liraglutide in opioid use disorder are now underway.
What makes this research particularly compelling is that these drugs already have established safety records. That existing approval pathway could accelerate their arrival in addiction treatment — provided clinical trials confirm efficacy in humans. Two alcohol-focused trials are already testing weekly exenatide injections in patients with alcohol use disorder.
Still, the evidence remains heavily weighted toward animals, and the review is candid about the gaps: most studies examined reward rather than compulsive use despite consequences, the true hallmark of addiction. How these drugs perform in severe dependence, whether effects differ between men and women, and what long-term use looks like all remain open questions. The preclinical foundation is real; the path to prescription is not yet certain.
Millions of people struggle each year with addiction to alcohol, opioids, cocaine, and nicotine, yet the medications available to treat these conditions remain limited and often ineffective. Relapse rates stay stubbornly high. Now researchers are asking whether drugs already sitting in medicine cabinets across the world—medications prescribed for diabetes and obesity—might offer a new path forward. A recent review published in the British Journal of Pharmacology examines how GLP-1 receptor agonists, a class of drugs including semaglutide, liraglutide, and exenatide, could dampen the brain's reward signals and reduce the compulsive drive to seek drugs and alcohol.
The mechanism is elegant in its simplicity. GLP-1 is a hormone that regulates blood sugar and appetite, but it also circulates in the brain, where it acts as a neurotransmitter in regions tied to pleasure and motivation. When someone uses alcohol or cocaine or heroin, dopamine floods the mesolimbic reward pathway—the brain's pleasure circuit—reinforcing the behavior and making the person want to repeat it. Animal studies show that GLP-1 drugs can blunt this dopamine surge without completely shutting down the reward system itself. In rats and mice, liraglutide, exenatide, and dulaglutide all reduced alcohol consumption and the rewarding sensation associated with drinking. In nonhuman primates, exenatide and liraglutide decreased drinking in alcohol-prone African vervet monkeys without causing nausea or vomiting. Dulaglutide proved particularly effective, consistently lowering drinking in both male and female rats without the animals developing tolerance to the drug.
The promise extends beyond alcohol. Preclinical evidence suggests GLP-1 agonists can reduce cocaine self-administration and relapse-like seeking behavior in multiple animal species. Exenatide has shown the ability to decrease dopamine release after cocaine use and lower the frequency of relapse attempts. Nicotine addiction research has produced similarly encouraging results: animal studies found that exenatide reduced nicotine self-administration and reward-related behaviors, and an early human pilot trial reported that exenatide combined with nicotine replacement therapy improved smoking abstinence and reduced cravings. Rodent studies hint at potential benefits for opioid dependence as well, though the evidence remains mixed. Human trials are now underway to test whether liraglutide can reduce opioid cravings in patients with opioid use disorder.
What makes this research particularly intriguing is that GLP-1 drugs already have established safety profiles. Semaglutide, liraglutide, exenatide, and dulaglutide are approved and widely used for Type 2 diabetes and obesity. This means they could potentially reach addiction treatment settings faster than entirely new medications, provided clinical trials demonstrate they actually work in humans. Two alcohol-focused clinical trials are already exploring whether patients with alcohol use disorder can reduce heavy drinking days and decrease cravings using weekly injections of exenatide. Additional studies involving nicotine and opioid dependence are underway.
Yet the evidence remains heavily weighted toward animal studies. The review emphasizes that human data is limited and early, and that many animal models have focused on the rewarding effects of substances rather than on continued use despite negative consequences—the hallmark of true addiction. The researchers also note that GLP-1 agonists may influence stress pathways linked to relapse, reducing anxiety-like behaviors during withdrawal, though these effects are complex and not fully understood. The drugs appear to work even when substances are administered intravenously, suggesting the mechanism goes beyond simple appetite suppression.
Before these medications can be recommended for addiction treatment, larger clinical trials must answer several critical questions: How do they perform in people with severe substance dependence? Do they work differently in men and women? What are the long-term safety and effectiveness profiles? The review makes clear that while the preclinical foundation is promising, the leap from rat studies to human prescription remains substantial. The path forward is real, but it is not yet certain.
Citas Notables
GLP-1 receptor agonists reduced dopamine release following stimulatory effects produced by alcohol, cocaine, nicotine, and amphetamines in animal studies, without consistently suppressing baseline dopamine signaling.— British Journal of Pharmacology review
Larger clinical trial studies are needed before these medications are prescribed for individuals who have an addiction.— Review authors
La Conversación del Hearth Otra perspectiva de la historia
Why would a drug designed to manage blood sugar suddenly help someone stop drinking or using cocaine?
GLP-1 doesn't just live in the pancreas. It's also a messenger in the brain, particularly in regions that handle reward and motivation. When you use a substance, dopamine floods those circuits and reinforces the behavior. GLP-1 drugs seem to dampen that dopamine signal—not eliminate it, but reduce it enough that the craving weakens.
So it's like turning down the volume on desire itself?
In a way, yes. But it's more selective than that. The drugs don't seem to suppress baseline dopamine—the normal motivation to eat, work, connect with people. They appear to specifically reduce the dopamine surge triggered by addictive substances. At least in animals, that distinction matters.
The source mentions animal studies extensively. How much should we trust those results in humans?
That's the honest question the researchers are asking too. Rats and monkeys show promise, but addiction in humans involves stress, learning, genetics, environment—layers of complexity that a lab model can't fully capture. The early human trials are small and preliminary. We're still in the "this might work" phase, not the "this works" phase.
What's the advantage of using a drug that's already approved for diabetes?
Speed and safety data. If you're developing a brand-new addiction medication, you spend years proving it won't harm people. These GLP-1 drugs have already been through that process for millions of patients. If they prove effective for addiction, they could reach people much faster than waiting for a novel drug to clear all the regulatory hurdles.
Are there downsides?
Nausea and reduced appetite are known side effects. But interestingly, the animal studies show the drugs reduce drug-seeking even when the substance is injected directly into the bloodstream, bypassing the stomach entirely. So the effect isn't just about making food less appealing. That's actually encouraging—it suggests the mechanism is real and neurological, not just appetite suppression.
What happens next?
Clinical trials. Two are already testing exenatide in people with alcohol use disorder. Others are exploring nicotine and opioid dependence. The real test is whether what works in a rat cage translates to a person struggling with addiction in the real world. That's where we'll find out if this is genuinely transformative or just a promising dead end.